Effect of Propolis on Non-alcoholic fatty liver disease

Effect of Propolis on liver functional indexes in patients with Non-alcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20161023030445N2

Enrollment

Registered

2018-03-26

Start date

2017-12-22

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease (NAFLD). Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Control group: placebo containing starch, oral capsule, 500 mg, twice a day for three months with standard treatment. Intervention 2: Intervention group: Propolis, oral capsule, 500 mg

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: subjects over 20 years old subjects diagnosed with NAFLD by increased levels of ALT and AST Confirmation of NAFLD in Sonography report

Exclusion criteria

Exclusion criteria: viral hepatitis or autoimmune diabetes women who were pregnant or lactating Use of effective drugs on liver tests in the last 2 months (Statins, Glitazones , Chlorpromazine , Vit E, OCP , Anabolic Steroids, Thionamides , etc.) Hemochromatosis Cirrhosis Alcohol consumption of more than 140cc in men and 70 cc in women per week Infectious diseases herbal allergies history of allergic reactions to bee products.

Design outcomes

Secondary

Measure	Time frame
Fasting Blood Serum. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;TNFa. Timepoint: in the beginning and end of Intervention. Method of measurement: Pg/ml by using specific serum kit.;Interleukin 6. Timepoint: in the beginning and end of Intervention. Method of measurement: Pg/ml by using specific serum kit.	—

Primary

Measure	Time frame
Alanine Aminotransferase (ALT). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Aspartate Aminotransferase (AST). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Grade of fatty liver. Timepoint: in the beginning and end of Intervention. Method of measurement: Sonography.;Alkaline Phosphatase (ALP). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Body Mass Index (BMI). Timepoint: in the beginning and end of Intervention. Method of measurement: kg/m2 by measuring height and weight and use of scale.;Gamma glutamyl transpeptidase. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Albumin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Ferritin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Bilirubin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Cholestrol. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Triglyceride. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;High Density Lipoprotein (HDL). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Low Density Lipoprotein (LDL). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.	—

Measure

Time frame

Alanine Aminotransferase (ALT). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Aspartate Aminotransferase (AST). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Grade of fatty liver. Timepoint: in the beginning and end of Intervention. Method of measurement: Sonography.;Alkaline Phosphatase (ALP). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Body Mass Index (BMI). Timepoint: in the beginning and end of Intervention. Method of measurement: kg/m2 by measuring height and weight and use of scale.;Gamma glutamyl transpeptidase. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Albumin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Ferritin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Bilirubin. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Cholestrol. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Triglyceride. Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;High Density Lipoprotein (HDL). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.;Low Density Lipoprotein (LDL). Timepoint: in the beginning and end of Intervention. Method of measurement: mg/dl by using specific serum kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Vahid Yousefinejad

Liver & Digestive Research Center,Kurdistan university of medical sciences

hooman56y@yahoo.com+98 87 3324 7855

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026